Spyre Therapeutics, Inc.
NASDAQ:SYREBiotechnology
+$1.21 today
- Market cap
- $9.64B
- Beta
- 3.06
- P/E (TTM)
- -171.1
- EPS (TTM)
- -$0.52
Volume 1.37M
Average 1.17M
SYRE Total Current Liabilities
All obligations due within one year.
Spyre Therapeutics, Inc.NASDAQ: SYRE
Total Current Liabilities · Q3 FY2026 · quarter ended Sep 2026
Total current liabilities falls 13.2% from a year ago
Total current liabilities stood at $40.14M at the end of Q3 FY2026, down 13.2% from a year earlier and down 36.6% from the prior quarter. Over 3 fiscal years it compounded at +58.8% a year.
Context
- Total current liabilities amounted to 3.7% of total assets at the end of Q3 FY2026, down 5.5 pp from a year earlier.
- Total current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps falling in the next quarterly balance sheet after a -13.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 58.69M USD
- Year-over-year change
- +8.6%
- 4-year CAGR
- +30.6%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 58.69M | +8.6% |
| FY2024 | 2024-12-31 | 54.06M | +69.1% |
| FY2023 | 2023-12-31 | 31.98M | +118.2% |
| FY2022 | 2022-12-31 | 14.66M | -27.2% |
| FY2021 | 2021-12-31 | 20.14M | — |
Total Current Liabilities vs competitors
How SYRE compares with its peers on the latest reported figures
- Peers report in different currencies, so total current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -13.2% is the 6th highest of 8, against a peer median of +27.2%.
- Total current liabilities amounts to 3.7% of total assets for SYRE, versus a peer median of 14.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $109.57M USD | +44.5% | +10.5% | 21.7% | |
| Jun 2026 | €71.69M EUR | -36.2% | +7.0% | 15.5% | |
| Mar 2026 | $41.7M USD | -5.3% | +14.0% | 12.6% | |
| Sep 2026 | $40.14M USD | -13.2% | +58.8% | 3.7% | |
| Mar 2026 | $38.36M USD | +49.9% | +32.8% | 20.2% | |
| Mar 2026 | $27.37M USD | +27.2% | +9.3% | 13.8% | |
UPBUpstream Bio, Inc. | Mar 2026 | $13.67M USD | +42.9% | +40.4% | 4.3% |
| Mar 2026 | €11.4M EUR | -29.6% | -0.1% | 23.3% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | Sep 2025 | €9.51M EUR | — | — | 5.7% |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding SYRE) | — | +27.2% | +10.5% | 14.6% | |
Competitors are the stored peer set for SYRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 15.14M | 34.86M | 188.89M | 89.42M | 85.72M |
| Short-term Investments | 77.99M | 20.85M | 150.38M | 513.67M | 670.81M |
| Net Receivables | 815K | 375K | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 6.17M | 2.25M | 5.39M | 21.25M |
| Total Current Assets | 98.89M | 62.26M | 341.53M | 608.47M | 777.78M |
| Property, Plant & Equipment (Net) | 8.36M | 6.65M | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 2.68M | 2.24M | 331K | 10K | 0 |
| Total Non-current Assets | 11.04M | 8.89M | 331K | 10K | 0 |
| Total Assets | 109.93M | 71.14M | 341.86M | 608.48M | 777.78M |
| Account Payables | 3.32M | 677K | 896K | 666K | 8.9M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 2.36M | 517K | 0 | 0 | 0 |
| Other Current Liabilities | 4.99M | 4.92M | 5.93M | 31.27M | 30.94M |
| Total Current Liabilities | 20.14M | 14.66M | 31.98M | 54.06M | 58.69M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 1.22M | 2.18M | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 125.87M | 36.62M | 3.86M |
| Total Non-current Liabilities | 5.84M | 6.18M | 125.87M | 36.62M | 3.86M |
| Total Liabilities | 25.99M | 20.84M | 157.84M | 90.68M | 62.55M |
| Common Stock | 5K | 6K | 10K | 13K | 15K |
| Retained Earnings | (341.81M) | (425.62M) | (764.41M) | (972.43M) | (1.13B) |
| Accumulated OCI | (20K) | (48K) | 302K | 180K | 869K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 83.94M | 50.31M | 184.02M | 517.8M | 715.24M |
| Total Debt | 5.06M | 4.63M | 0 | 0 | 0 |
| Net Debt | (10.08M) | (30.23M) | (188.89M) | (89.42M) | (85.72M) |
Spyre Therapeutics, Inc.
NASDAQ:SYRE
Intrinsic Alpha fair value
Locked
Current Price
$101.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.